• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Longevity Acquisition Corporation

    3/31/21 1:21:13 PM ET
    $LOAC
    Business Services
    Finance
    Get the next $LOAC alert in real time by email
    POS AM 1 tm2111323d1_posam.htm POS AM

     

    As filed with the Securities and Exchange Commission on March 31, 2021

    Registration No. 333-226699

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT TO NO. 1

    TO

    FORM S-1

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Longevity Acquisition Corporation

    (Exact name of registrant as specified in its charter)

     

    British Virgin Islands   6770   N/A
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification Number)

     

    5th Floor, 9 Bond Court
    Leeds
    LS1 2JZ
    United Kingdom
    Tel: +44 (0) 113 895 0130

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)​ 

     

    Cogency Global Inc.
    10 East 40th Street, 10th Floor
    New York, N.Y. 10016
    +1(800)221-0102

     

    (Name, address, including zip code, and telephone number, including area code, of agent for service)​

     

    Copies to:

     

    Steven V. Bernard
    Bradley L. Finkelstein
    Wilson Sonsini Goodrich & Rosati
    Professional Corporation
    650 Page Mill Road
    Palo Alto,
    California 94304-1050
    (650) 493-9300
      Duncan Peyton
    Chief Executive Officer
    4D pharma plc
    5th Floor, 9 Bond Court
    Leeds
    LS1 2JZ
    United Kingdom
    +44(0) 113 895 0130

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. x

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer ¨ (Do not check if a smaller reporting company)   Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    DEREGISTRATION OF UNSOLD SECURITIES

     

    This Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (Registration 333-226699) of Longevity Acquisition Corporation (the “Company”), initially filed with the Securities and Exchange Commission on August 8, 2018, and amended by Amendment No. 1 on August 15, 2018, and amended by Amendment No 2 on August 23, 2018 (the “Registration Statement”), hereby further amends the Registration Statement to deregister all securities registered pursuant to the Registration Statement and not otherwise sold as of the date this Post-Effective Amendment No. 1 is filed.

     

    On October 21, 2020, the Company, 4D pharma plc (“4D Pharma”), a public limited company incorporated under the laws of England and Wales, and Dolphin Merger Sub Limited (“Merger Sub”), a British Virgin Islands company limited by shares and a wholly-owned subsidiary of 4D Pharma, entered into an Agreement and Plan of Merger (the “Merger Agreement”). The Merger Agreement contemplates that, subject to the terms and conditions set forth therein, the Company will merge with and into Merger Sub (the “Merger”), with Merger Sub continuing as the surviving corporation as a wholly owned subsidiary of 4D Pharma. The Merger became effective on March 22, 2021, upon the filing and effectiveness, as agreed between 4D Pharma and the Company, of the articles of merger containing the plan of the merger and such other information as is required by the BVI Business Companies Act of 2004 and the resolution amending Merger Sub’s memorandum and articles of association and their amendment are registered by the registrar of corporate affairs of the British Virgin Islands.

     

    As a result of the Merger, the Company has terminated all offerings of its securities pursuant to the Registration Statement and hereby removes from registration all securities of the Company registered under the Registration Statement as of the date of this Post-Effective Amendment. In that regard, and for the avoidance of doubt, any selling stockholders of the Company under the Registration Statement no longer own any registered securities, including any units, ordinary shares, warrants or rights, as a result of the Merger.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Post-Effective Amendment to Form S-1 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized on March 31, 2021.

     

      Longevity Acquisition Corporation
         
      By: /s/ Duncan Peyton
        Name: Duncan Peyton
        Title: Director
         
      By: /s/ Alexander Stevenson
        Name: Alexander Stevenson
        Title: Director

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name   Position   Date
    /s/ Duncan Peyton   Director   March 31, 2021
    Duncan Peyton        
             
    /s/ Alexander Stevenson   Director   March 31, 2021
    Alexander Stevenson        
             
    Authorized Representative in the United States:    
             
    4D Pharma Delaware Inc.        
             
    /s/ Glenn Dourado        
    Name: Glenn Dourado        
    Title: President        
    Date: March 31, 2021        

     

     

     

    Get the next $LOAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LOAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LOAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC). 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’ Warrants of Longevity assumed by 4D pharma in the Merger are currently expected to begin trading on Nasdaq under the ticker symbol ‘LBPSW’ tomorrow, Tuesday, March 23, 2021. Lo

    3/22/21 3:00:00 AM ET
    $LOAC
    Business Services
    Finance

    Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders

    NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its special meeting of shareholders, which was held on March 17, 2021. At the special meeting, shareholders of the Company approved the merger, including a certain agreement and plan of merger, dated as of October 21, 2020, by and among 4d pharma plc, the Company and Dolphin Merger Sub Limited, and the related agreements and transactions contemplated thereby. About LOAC LOAC is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of

    3/18/21 8:00:00 AM ET
    $LOAC
    Business Services
    Finance

    4D Pharma to Present at Upcoming Investor Conferences in March

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences: Chardan's Virtual 3rd Annual Microbiome Medicines Summit: Monday March 8, 2021 at 11:45 am ET (16:45 GMT). H.C. Wainwright Global Life Sciences Conference: Available on-demand starting Tuesday, March 9, 2021 at 7:00 am ET (12:00 GMT). Oppenheimer’s 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 8:40 am ET (12:40 GMT). About 4D pharma Founded in February 2014, 4D pharma is a w

    3/3/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    SEC Filings

    View All

    SEC Form EFFECT filed by Longevity Acquisition Corporation

    EFFECT - Longevity Acquisition Corp (0001743858) (Filer)

    4/7/21 12:15:42 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form 15-15D filed by Longevity Acquisition Corporation

    15-15D - Longevity Acquisition Corp (0001743858) (Filer)

    4/1/21 1:05:04 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form POS AM filed by Longevity Acquisition Corporation

    POS AM - Longevity Acquisition Corp (0001743858) (Filer)

    3/31/21 1:21:13 PM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Leadership Updates

    Live Leadership Updates

    View All

    4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

    LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. “John will be an important addition to 4D pharma’s management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expert

    3/1/21 7:00:00 AM ET
    $LOAC
    Business Services
    Finance

    $LOAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 3:16:03 PM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/16/21 7:36:20 AM ET
    $LOAC
    Business Services
    Finance

    SEC Form SC 13G/A filed

    SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

    2/12/21 4:21:17 PM ET
    $LOAC
    Business Services
    Finance